Treatment refractory depression in the elderly: The role of maintenance electroconvulsive therapy

2006 ◽  
Vol 4 (2) ◽  
pp. 79-83
Author(s):  
Bruce Rudisch ◽  
William M. McDonald
Keyword(s):  
Electroconvulsive Therapy ◽  
The Elderly ◽  
Refractory Depression ◽  
Treatment Refractory

scholarly journals Treatment-Refractory Depression in the Elderly

1999 ◽  
Vol 01 (06) ◽  
pp. 188-190
Author(s):  
Patrick Brooke ◽  
Mari Jones-Ritson ◽  
Roger Bullock
Keyword(s):  
The Elderly ◽  
Refractory Depression ◽  
Treatment Refractory

Strategies for Treatment Refractory Depression

2001 ◽  
Vol 14 (6) ◽  
pp. 478-487
Author(s):  
Jessica L. Goren
Keyword(s):  
Treatment Period ◽  
Electroconvulsive Therapy ◽  
Treatment Options ◽  
Antidepressant Therapy ◽  
Refractory Depression ◽  
Augmentation Strategies ◽  
Treatment Refractory

Ten to thirty percent of patients do not respond adequately to antidepressant therapy. Absolute treatment refractory depression occurs in up to 10% of patients with depression. To date, few studies have addressed this issue. Several treatment options are available for refractory depression, including increasing the dose, extending the treatment period, switching and augmentation strategies, and electroconvulsive therapy. This paper will review some strategies available for treatment refractory depression.

scholarly journals Association of VEGF With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei Zheng ◽  
Li-Mei Gu ◽  
Yan-Ling Zhou ◽  
Cheng-Yu Wang ◽  
Xiao-Feng Lan ◽  
...  
Keyword(s):  
Rating Scale ◽  
Chinese Patients ◽  
Repeated Dose ◽  
Vascular Endothelial ◽  
Refractory Depression ◽  
Preliminary Study ◽  
Treatment Refractory ◽  
Endothelial Growth Factor ◽  
Intravenous Ketamine

Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD).Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) anhedonia item at baseline, day 13 and 26. Plasma VEGF concentrations were examined at the same time points as the MADRS.Results: Despite a significant reduction in anhedonia symptoms in individuals with treatment-refractory MDD (n = 59) or BD (n = 19) after they received repeated-dose ketamine infusions (p < 0.05), no significant changes in plasma VEGF concentrations were found at day 13 when compared to baseline (p > 0.05). The alteration of plasma VEGF concentrations did not differ between antianhedonic responders and non-responders at days 13 and 26 (all ps > 0.05). Additionally, no significant correlations were observed between the antianhedonic response to ketamine and plasma VEGF concentrations (all ps > 0.05).Conclusion: This preliminary study suggests that the antianhedonic effects of ketamine are not mediated by VEGF.

Safety of Electroconvulsive Therapy in Treatment-Refractory Depression in the Setting of Multiple Sclerosis

2019 ◽  
Vol 35 (3) ◽  
pp. e36-e37 ◽  
Author(s):  
Jennifer Oilgmueller ◽  
Ashish Sharma ◽  
Matthew Egbert ◽  
Valery Tran
Keyword(s):  
Multiple Sclerosis ◽  
Electroconvulsive Therapy ◽  
Refractory Depression ◽  
Treatment Refractory

Prospective Memory Development Across the Lifespan

2020 ◽  
Vol 25 (3) ◽  
pp. 162-173 ◽  
Author(s):  
Sascha Zuber ◽  
Matthias Kliegel
Keyword(s):  
Prospective Memory ◽  
Healthy Aging ◽  
Present Model ◽  
Current Knowledge ◽  
Well Being ◽  
The Elderly ◽  
Cognitive Factors ◽  
Everyday Functioning ◽  
Integrative Framework

Abstract. Prospective Memory (PM; i.e., the ability to remember to perform planned tasks) represents a key proxy of healthy aging, as it relates to older adults’ everyday functioning, autonomy, and personal well-being. The current review illustrates how PM performance develops across the lifespan and how multiple cognitive and non-cognitive factors influence this trajectory. Further, a new, integrative framework is presented, detailing how those processes interplay in retrieving and executing delayed intentions. Specifically, while most previous models have focused on memory processes, the present model focuses on the role of executive functioning in PM and its development across the lifespan. Finally, a practical outlook is presented, suggesting how the current knowledge can be applied in geriatrics and geropsychology to promote healthy aging by maintaining prospective abilities in the elderly.

Sign in / Sign up

Export Citation Format

Share Document